ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease (1987)

Loft, S. ; Simonsen, K. ; Evald, T. ; [et al.]

Springer

European journal of clinical pharmacology 33 (1987), S. 89-91

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: antipyrine ; prednisolone ; pharmacokinetics ; obstructive lung disease ; hepatic drug metabolism

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Summary The influence of prednisolone on the elimination of antipyrine has been investigated. The one-sample antipyrine clearance was estimated in 23 outpatients with obstructive lung disease before and after treatment with prednisolone 30 or 50 mg/day for 7 days. During prednisolone administration antipyrine clearance decreased from 54.9±14.8 to 51.7±14.6 ml/min (mean±SD; p〈0.05). The results indicate that prednisolone decreases the rate of antipyrine elimination, but not to an extent suggesting a clinically important change in hepatic drug metabolism.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/BF00610387

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Chronic non-asthmatic cough is not affected by inhaled beclomethasone dipropionate (1989)

EVALD, T. ; MUNCH, E. P. ; KOK-JENSEN, A.

Oxford, UK : Blackwell Publishing Ltd

Allergy 44 (1989), S. 0

add to mindlist on the mindlist

Details

ISSN: 1398-9995

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: Thirty-one patients with a dry cough for at least 1 h duration in more than half of the last 30 days and with no recent respiratory infection participated in a clinical trial to evaluate the effect of inhaled beclomethasone dipropionate (BDP). Lung function was normal and reversibility was excluded by spirometry before and after bronchodilator and by no diurnal variation in home peak flow monitoring. Only one had significant eosinophilia and only three were mildly hyperreactive by bronchial provocation with histamine. After a 1-week run-in period the patients were randomly allocated to receive either BDP 4 puffs of 50 μg b.i.d., or placebo. After 2 weeks the patients were crossed over and received the alternative treatment for another 2-week period. The degree of cough, disturbance of night sleep and peak expiratory flow morning and evening were recorded daily in a diary. Spirometry was performed at each control visit. A significant period effect from run-in to period 1 and/or from period 1 to period 2 was demonstrated for cough and disturbance at night but not for peak flow or spirometry. However, no significant treatment effect was found for any of the measured variables.